ProCE Banner Activity

Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer

Slideset

Download this focused slideset on incorporating adjuvant CDK4/6 inhibitors into the treatment of patients with HR-positive/HER2-negative early-stage breast cancer, including patient selection, toxicity management, and adherence considerations.

Released: May 01, 2024

Expiration: April 30, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner